Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

1,3,4-Oxadiazoles as Anticancer Agents: A Review

Author(s): Greesh Kumar, Rajnish Kumar*, Avijit Mazumder, Salahuddin and Upendra Kumar

Volume 19, Issue 3, 2024

Published on: 10 August, 2023

Page: [257 - 267] Pages: 11

DOI: 10.2174/1574892818666230727102928

Price: $65

Abstract

Among the deadliest diseases, cancer is characterized by tumors or an increased number of a specific type of cell because of uncontrolled divisions during mitosis. Researchers in the current era concentrated on the development of highly selective anticancer medications due to the substantial toxicities of conventional cytotoxic drugs. Several marketed drug molecules have provided resistance against cancer through interaction with certain targets/growth factors/enzymes, such as Telomerase, Histone Deacetylase (HDAC), Methionine Aminopeptidase (MetAP II), Thymidylate Synthase (TS), Glycogen Synthase Kinase-3 (GSK), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Focal Adhesion Kinase (FAK), STAT3, Thymidine phosphorylase, and Alkaline phosphatase. The molecular structure of these drug molecules contains various heterocyclic moieties that act as pharmacophores. Recently, 1,3,4- oxadiazole (five-membered heterocyclic moiety) and its derivatives attracted researchers as these have been reported with a wide range of pharmacological activities, including anti-cancer. 1,3,4- oxadiazoles have exhibited anti-cancer potential via acting on any of the above targets. The presented study highlights the synthesis of anti-cancer 1,3,4-oxadiazoles, their mechanism of interactions with targets, along with structure-activity relationship concerning anti-cancer potential.

Next »
[1]
Smith R, Rennie D. Evidence-based medicine--an oral history. JAMA 2014; 311(4): 365-7.
[http://dx.doi.org/10.1001/jama.2013.286182] [PMID: 24449049]
[2]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[3]
Shahzad SA, Yar M, Bajda M, et al. Synthesis, thymidine phosphorylase inhibition and molecular modeling studies of 1,3,4-oxadiazole-2-thione derivatives. Bioorg Chem 2015; 60: 37-41.
[http://dx.doi.org/10.1016/j.bioorg.2015.04.003] [PMID: 25920005]
[4]
Sun J, Li MH, Qian SS, et al. Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors. Bioorg Med Chem Lett 2013; 23(10): 2876-9.
[http://dx.doi.org/10.1016/j.bmcl.2013.03.068] [PMID: 23582273]
[5]
Hughes TV, Xu G, Wetter SK, et al. A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity. Bioorg Med Chem Lett 2008; 18(17): 4896-9.
[http://dx.doi.org/10.1016/j.bmcl.2008.07.057] [PMID: 18678484]
[6]
Zhang S, Luo Y, He LQ, et al. Synthesis, biological evaluation, and molecular docking studies of novel 1,3,4-oxadiazole derivatives possessing benzotriazole moiety as FAK inhibitors with anticancer activity. Bioorg Med Chem 2013; 21(13): 3723-9.
[http://dx.doi.org/10.1016/j.bmc.2013.04.043] [PMID: 23673215]
[7]
Alam MM, Almalki ASA, Neamatallah T, Ali NM, Malebari AM, Nazreen S. Synthesis of new 1, 3, 4-oxadiazole-incorporated 1, 2, 3-triazole moieties as potential anticancer agents targeting thymidylate synthase and their docking studies. Pharmaceuticals 2020; 13(11): 390.
[http://dx.doi.org/10.3390/ph13110390] [PMID: 33202652]
[8]
Bilal MS, Ejaz SA, Zargar S, et al. Computational investigation of 1, 3, 4 oxadiazole derivatives as lead inhibitors of vegfr 2 in comparison with EGFR: Density functional theory, molecular docking and molecular dynamics simulation studies. Biomolecules 2022; 12(11): 1612.
[http://dx.doi.org/10.3390/biom12111612] [PMID: 36358960]
[9]
Pidugu VR, Yarla NS, Pedada SR, Kalle AM, Satya AK. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity. Bioorg Med Chem 2016; 24(21): 5611-7.
[http://dx.doi.org/10.1016/j.bmc.2016.09.022] [PMID: 27665180]
[10]
Zhang XM, Qiu M, Sun J, et al. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents. Bioorg Med Chem 2011; 19(21): 6518-24.
[http://dx.doi.org/10.1016/j.bmc.2011.08.013] [PMID: 21962523]
[11]
Saitoh M, Kunitomo J, Kimura E, et al. 2-3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β with good brain permeability. J Med Chem 2009; 52(20): 6270-86.
[http://dx.doi.org/10.1021/jm900647e] [PMID: 19775160]
[12]
Malojirao VH, Girimanchanaika SS, Shanmugam MK, et al. Novel 1, 3, 4-oxadiazole targets STAT3 signaling to induce antitumor effect in lung cancer. Biomedicines 2020; 8(9): 368.
[http://dx.doi.org/10.3390/biomedicines8090368] [PMID: 32967366]
[13]
Iqbal Z, Iqbal A, Ashraf Z, Latif M, Hassan M, Nadeem H. Synthesis and docking studies of N ‐(5‐(alkylthio)‐1,3,4‐oxadiazol‐2‐ yl)methyl)benzamide analogues as potential alkaline phosphatase inhibitors. Drug Dev Res 2019; 80(5): ddr.21542.
[http://dx.doi.org/10.1002/ddr.21542] [PMID: 31032540]
[14]
Cisar JS, Pietsch C, DeRatt LG, et al. N -heterocyclic 3-pyridyl carboxamide inhibitors of DHODH for the treatment of acute myelogenous leukemia. J Med Chem 2022; 65(16): 11241-56.
[http://dx.doi.org/10.1021/acs.jmedchem.2c00788] [PMID: 35925768]
[15]
Barreca M, Spanò V, Raimondi MV, et al. Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. Eur J Med Chem 2021; 1: 100004.
[http://dx.doi.org/10.1016/j.ejmcr.2021.100004]
[16]
Barreca M, Spanò V, Rocca R, et al. Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas. Eur J Med Chem 2022; 243: 114744.
[http://dx.doi.org/10.1016/j.ejmech.2022.114744] [PMID: 36242921]
[17]
Labbozzetta M, Barreca M, Spanò V, et al. Novel insights on [1,2]oxazolo[5,4‐ e ]isoindoles on multidrug resistant acute myeloid leukemia cell line. Drug Dev Res 2022; 83(6): 1331-41.
[http://dx.doi.org/10.1002/ddr.21962] [PMID: 35749723]
[18]
Noolvi MN, Patel HM, Kamboj S, Kaur A, Mann V. 2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazoles: Search for anticancer agents. Eur J Med Chem 2012; 56: 56-69.
[http://dx.doi.org/10.1016/j.ejmech.2012.08.012] [PMID: 22960694]
[19]
Asati V, Mahapatra DK, Bharti SK. Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents. Eur J Med Chem 2014; 87: 814-33.
[http://dx.doi.org/10.1016/j.ejmech.2014.10.025] [PMID: 25440883]
[20]
Peterson QP, Hsu DC, Goode DR, Novotny CJ, Totten RK, Hergenrother PJ. Procaspase-3 activation as an anti-cancer strategy: Structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3. J Med Chem 2009; 52(18): 5721-31.
[http://dx.doi.org/10.1021/jm900722z] [PMID: 19708658]
[21]
Mishra AK, Kumar A, Sahu JK. Recent advancements in biological activities of oxadiazole and their derivatives: A Review. Lett Org Chem 2020; 17(6): 409-29.
[http://dx.doi.org/10.2174/1570178617666191220115426]
[22]
De SS, Khambete MP, Degani MS. Oxadiazole scaffolds in anti-tuberculosis drug discovery. Bioorg Med Chem Lett 2019; 29(16): 1999-2007.
[http://dx.doi.org/10.1016/j.bmcl.2019.06.054] [PMID: 31296357]
[23]
Somani RR, Shirodkar PY, et al. Oxadiazole: A biologically important heterocycle. Chem Inform 2011; 42(10)
[24]
Sanchit S, Pandeya SN, et al. Various approaches for synthesis of oxadiazole derivatives. Int J Res Ayurveda Pharm 2011; 4: 1124.
[25]
Boström J, Hogner A, Llinàs A, Wellner E, Plowright AT. Oxadiazoles in medicinal chemistry. J Med Chem 2012; 55(5): 1817-30.
[http://dx.doi.org/10.1021/jm2013248] [PMID: 22185670]
[26]
Zarghi A, Hajimahdi Z. Substituted oxadiazoles: A patent review (2010 – 2012). Expert Opin Ther Pat 2013; 23(9): 1209-32.
[http://dx.doi.org/10.1517/13543776.2013.797409] [PMID: 23663160]
[27]
Atmaram UA, Roopan SM. Biological activity of oxadiazole and thiadiazole derivatives. Appl Microbiol Biotechnol 2022; 106(9-10): 3489-505.
[http://dx.doi.org/10.1007/s00253-022-11969-0] [PMID: 35562490]
[28]
Salassa G, Terenzi A. Metal complexes of oxadiazole ligands: An overview. Int J Mol Sci 2019; 20(14): 3483.
[http://dx.doi.org/10.3390/ijms20143483] [PMID: 31315181]
[29]
Asai A, Matsuno K, Ogo N, Okawara T. Use of 1,3,4-oxadiazole derivative for anticancer Activity. US8796320B2, 2014.
[30]
Han Y, Kim Y, Sung Ko M, Lee J. Use of 1,3,4-oxadiazole derivative as a HDAC6 inhibitors. AU2016299485B2, 2017.
[31]
Neil GA, Guangming C, Gary MK, Ellen W. Use of 1,3,4-oxadiazole for nonsense Suppression. US-9611230-B2, 2017.
[32]
Bae M, Choi D, Han Y, Kim D, Kim Y, Lee J. Use of 1,3,4-oxadiazole derivative as HADC6 inhibitors. AU2016299484A1, 2018.
[33]
Francisco-Javier P, Luis C. Use of 1,3,4-oxadiazole derivative for Stemming bleeding and treating cancer. WO2020060963A1, 2020.
[34]
Salazar Y, Arevalo E A, Iglesias T. Use of 1,3,4-oxadiazole derivative as HDAC6 inhibitors. WO2020212479A1, 2020.
[35]
Sik Lee C, Taek Oh J, Hokeun Y, Hyeseung S, Hyunjin Michael K. Use of 1,3,4-oxadiazole derivative as Histone deacetylase 6 inhibitors. WO2020240492A1, 2020.
[36]
Asai A, Matsuno K, Takahashi O, Okawara T. Use of 1,3,4-oxadiazole derivative for anticancer activity. WO2021126118A1, 2021.
[37]
Chang Kon Lee, Moo Sung Ko, Hyoun Yun Seok, Michael Kim Hyunjim. Use of 1,3,4-oxadiazole derivative as HDAC6 inhibitor. WO-20211210857-A1, 2021.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy